We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Anika Therapeutics Inc | NASDAQ:ANIK | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 28.36 | 11.41 | 45.09 | 0 | 09:09:53 |
From May 2023 to May 2024
By Adam L. Cataldo
Anika Therapeutics expects to release its treatment for rotator-cuff repairs in early 2024 after it received final 510(k) clearance from the U.S. Food and Drug Administration.
The Integrity Implant System is designed to promote healing by augmenting an injured tendon following rotator-cuff-repair procedures, the company said.
Based in Bedford, Mass., Anika Therapeutics is a joint-preservation company focused on early intervention orthopedics.
A limited market release of the system in the U.S. is expected to begin in the first quarter, the company said. A wider release in the U.S. and expansion into international markets will follow.
The U.S. market for rotator-cuff augmentation is estimated at $150 million and is growing at a nearly 7% compound annual growth rate over the next five years, the company said.
Write to Adam Cataldo at adam.cataldo@wsj.com.
(END) Dow Jones Newswires
August 17, 2023 19:42 ET (23:42 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Anika Therapeutics Chart |
1 Month Anika Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
